Ocugen completes dosing of GARDian3 trial for OCU410ST ahead of schedule
Ocugen have recently announced that they have completed enrolment and dosing in their pivotal phase 2/3 trial of OCU410ST ahead of schedule.
Search
Search results
Gene Therapy improves functional measures in XLRP
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
Genetic counselling
Genetic counsellors are specially trained healthcare professionals with extensive scientific knowledge who spend time talking to families living with inherited conditions.
New Young Persons Project from Retina UK
We are proud to launch our new Young Persons Project, which will play a significant role in providing impactful and timely support for young people with inherited sight loss and mental health challenges, across the UK.
Vision Zone 2026 – Melrose
Would you like to find out more about assistive technology, Support, Services, Groups, and much more? Vision Zone events bring together a variety of excellent services and charities covering your local area.
Vision Zone 2026 – Perth
Would you like to find out more about assistive technology, Support, Services, Groups, and much more? Vision Zone events bring together a variety of excellent services and charities covering your local area.
Opus genetics launches clinical trial for MERTK-related retinitis pigmentosa
Opus Genetics has launched an early-stage clinical trial of OPGx-MERTK, an investigational gene therapy for MERTK-related Retinitis Pigmentosa (RP), a condition that causes progressive vision loss due to photoreceptor degeneration.
Volunteering FAQs
These are some of the most commonly asked questions about volunteering for our charity.